S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning

Barinthus Biotherapeutics (BRNS) Earnings Date, Estimates & Call Transcripts

$3.14
-0.19 (-5.71%)
(As of 04/12/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 10Estimated
Actual EPS
(Mar. 20)
-$0.45 Beat By $0.10
Consensus EPS
(Mar. 20)
-$0.55
Skip Charts & View Estimated and Actual Earnings Data

BRNS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BRNS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Barinthus Biotherapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242($0.67)($0.59)($0.63)
Q2 20242($0.66)($0.59)($0.63)
Q3 20242($0.68)($0.58)($0.63)
Q4 20241($0.58)($0.58)($0.58)
FY 20247($2.59)($2.34)($2.47)
Q1 20251($0.71)($0.71)($0.71)
Q2 20251($0.71)($0.71)($0.71)
Q3 20251($0.73)($0.73)($0.73)
Q4 20251($0.72)($0.72)($0.72)
FY 20254($2.87)($2.87)($2.87)

BRNS Earnings Date and Information

Barinthus Biotherapeutics last released its earnings results on March 20th, 2024. The reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.10. Barinthus Biotherapeutics has generated ($1.92) earnings per share over the last year (($1.92) diluted earnings per share). Earnings for Barinthus Biotherapeutics are expected to decrease in the coming year, from ($2.60) to ($2.93) per share. Barinthus Biotherapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, May 10th, 2024 based off prior year's report dates.

Barinthus Biotherapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/10/2024
Estimated)
------- 
3/20/2024Q4 2023($0.55)($0.45)+$0.10($0.45)--
11/9/2023Q3 2023($0.62)($0.37)+$0.25($0.37)--
8/10/2023Q2 2023($0.59)($0.62)($0.03)($0.62)$0.65 million$0.33 million
5/12/2023Q1 2023($0.58)($0.48)+$0.10($0.48)$1.12 million$0.47 million
3/24/2023Q4 2022($0.43)($0.55)($0.12)($0.55)$3.07 million$6.46 million
11/10/2022Q3 2022($0.32)$0.22+$0.54$0.22$5.43 million$6.17 million
8/9/2022Q2 2022($0.41)$0.41+$0.82$0.41$2.95 million$17.06 million
5/11/2022Q1 2022($0.32)$0.07+$0.39$0.07$3.57 million$15.02 million
3/25/2022Q4 2021($0.36)($0.38)($0.02)($0.38)--
11/12/2021Q3 2021($0.50)($0.13)+$0.37($0.13)$1.65 million$0.02 million
8/12/2021Q2 2021($0.79)($0.64)+$0.15($0.64)$0.15 million$0.04 million
6/14/2021Q1 2021($1.21)($0.96)+$0.25($0.02)$0.10 million$0.22 million

Barinthus Biotherapeutics Earnings - Frequently Asked Questions

When is Barinthus Biotherapeutics's earnings date?

Barinthus Biotherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, May 10th, 2024 based off last year's report dates. Learn more on BRNS's earnings history.

Did Barinthus Biotherapeutics beat their earnings estimates last quarter?

In the previous quarter, Barinthus Biotherapeutics (NASDAQ:BRNS) reported ($0.45) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.55) by $0.10. Learn more on analysts' earnings estimate vs. BRNS's actual earnings.

How much revenue does Barinthus Biotherapeutics generate each year?

Barinthus Biotherapeutics (NASDAQ:BRNS) has a recorded annual revenue of $802,000.00.

How much profit does Barinthus Biotherapeutics generate each year?

Barinthus Biotherapeutics (NASDAQ:BRNS) has a recorded net income of -$73.35 million. BRNS has generated -$1.92 earnings per share over the last four quarters.

What is Barinthus Biotherapeutics's EPS forecast for next year?

Barinthus Biotherapeutics's earnings are expected to decrease from ($2.60) per share to ($2.93) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:BRNS) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners